NCT05125523招募中1 期
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activity of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.1 个研究点 分布在 1 个国家目标入组 264 人开始时间: 2021年12月28日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 264
- 试验地点
- 1
- 主要终点
- Number of participants with adverse events
研究概览
简要总结
The purpose of this study is to estimate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of Sirolimus for Injection (Albumin Bound) in patients with solid malignancies.
详细描述
This study will be conducted in two stages.
Stage 1: To evaluate the safety and tolerability of Sirolimus for Injection (Albumin Bound) in patients with advanced tumors, determine the MTD and RP2D. The dose escalation scheme using the accelerated titration design for dose 1 and the rolling-six design for the remaining doses.
Stage 2: To preliminarily assess the antitumor activity of Sirolimus for Injection (Albumin Bound). Patients will be assigned to different cohorts based on their tumor type.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-75 years (inclusive), no gender limitation.
- •Patients must have a histologically or cytologically confirmed advanced or metastatic tumor for which no effective standard therapy is available, or have failed or been intolerant to standard therapies.
- •At least one measurable lesion per RECIST version 1.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to
- •Life expectancy of ≥3 months.
- •Suitable organs and hematopoietic function should be available. Laboratory tests during screening should meet the appropriate criteria.
- •Signed informed consent form.
排除标准
- •Prior anticancer treatment or participation in another clinical study within 4 weeks (or 5 half-lives of the treated drug, whichever is longer) prior to the first dose of study drugs.
- •Patients who have undergone major surgery within 4 weeks prior to starting study treatment, or who have not fully recovered from previous surgery.
- •Unresolved toxicities from prior therapy greater than Grade 1 as per Common Terminology Criteria for Adverse Events (CTCAE) (except alopecia or any other toxicity without safety risks as judged by the investigator).
- •History of serious cardiovascular disease.
- •Central nervous system metastasis or meningeal metastasis with clinical symptoms, or other evidence that the patient's central nervous system metastasis or meningeal metastasis has not been controlled, and the investigator judges it to be unsuitable for inclusion.
- •Known prior hypersensitivity to study drugs or any component in their formulations.
- •Prior treatment with any mTOR inhibitor.
- •Has received a live or live-attenuated virus vaccine within 30 days prior to consent.
- •Uncontrollable active infection (CTCAE v5.0 ≥grade 2).
- •Use of strong inhibitors and inducers of CYP3A4 within 2 weeks prior to receiving the first dose of study drug and still need to continue using this class of drug.
- •History of autoimmune diseases, immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency, or organ transplant history.
- •HBsAg-positive with HBV viral load (VL) ≥1000 IU/mL; Hepatitis C Virus (HCV)-positive; Anti-treponema pallidum positive.
- •Women of child-bearing potential, or men whose partners are women of childbearing age, have not agree to use highly effective methods of contraception during dosing and for 6 months after study drug discontinuation; female patients has a positive serum pregnancy test within 7 days prior to receiving the first dose of study medication; lactating female.
- •Has history of other serious diseases judged by the investigator, which will threaten the safety of patients or interfere the study compliance, or other reasons are not suitable for participating in the study.
研究组 & 干预措施
Sirolimus for Injection (Albumin Bound)
Experimental
Stage 1：Multiple doses of Sirolimus for Injection (Albumin Bound) will be administered intravenously.
Stage 2：RP2D of Sirolimus for Injection (Albumin Bound) as determined during stage 1 will be administered intravenously.
干预措施: Sirolimus for Injection (Albumin Bound) (Drug)
结局指标
主要结局
Number of participants with adverse events
时间窗: Up to 3 years
Overall response rate (Stage 2)
时间窗: Up to 3 years
Dose-Limiting Toxicities (Stage 1)
时间窗: Cycle 1 (Up to 28 days)
Maximum tolerated dose (Stage 1)
时间窗: Up to 1.5 years
Recommended phase 2 dose (Stage 1)
时间窗: Up to 1.5 years
次要结局
- Disease Control Rate(Up to 3 years)
- Peak concentration (Cmax)(Day 1 of cycle 1 to Day 1 of cycle 4 (85 days))
- Elimination half-life (t1/2)(Day 1 of cycle 1 to Day 1 of cycle 4 (85 days))
- Progression-free Survival(Up to 3 years)
- 4ebp-1 phosphorylation level in blood samples(Up to 168 hours post dose)
- Clearance (CL)(Day 1 of cycle 1 to Day 1 of cycle 4 (85 days))
- Area under the plasma concentration versus time curve (AUC)(Day 1 of cycle 1 to Day 1 of cycle 4 (85 days))
- Peak time (Tmax)(Day 1 of cycle 1 to Day 1 of cycle 4 (85 days))
- Distribution volume (Vz)(Day 1 of cycle 1 to Day 1 of cycle 4 (85 days))
- Duration of Response(Up to 3 years)
- S6K phosphorylation level in blood samples(Up to 168 hours post dose)
- TSC1/2 status in tumor samples(Day 1 of cycle 1)
- PTEN status in tumor samples(Day 1 of cycle 1)
- PIK3CA status in tumor samples(Day 1 of cycle 1)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsAdvanced Solid TumorsMSI-H/dMMR TumorsCutaneous Squamous Cell CarcinomaUrothelial Carcinoma, HCCEsophageal Squamous Cell CarcinomaSmall-cell Lung CancerCervical CancerMerkel Cell CarcinomaMesotheliomaPD-L1 Amplified Tumor (9p24.1)Cyclin-dependent Kinase 12 Mutated TumorsBasal Cell Carcinoma (Unresectable or Metastatic)Sarcomatoid Renal Cell CarcinomaClear Cell Ovarian or Endometrial CarcinomaAnal CarcinomaSquamous Cell Penile CarcinomaNasopharyngeal CarcinomaDNA Polymerase Epsilon Mutated Tumors (P286R and V411L)NCT04272034Incyte Corporation105
招募中
1 期
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918.AnemiaNCT05773586Ascentage Pharma Group Inc.105
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic InsufficiencySafety, Tolerability, and PK of NBI-98854 in Hepatically Impaired SubjectsNCT01916993Neurocrine Biosciences24
已完成
1 期
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-99677 in Healthy Adult Japanese Participants.Healthy VolunteersNCT04958291Celgene25
已完成
1 期
Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard TherapySolid TumorsNCT02499224CellabMED39